Control Of Gastrointestinal Tumour Progression By Therapeutic Interference With Myeloid Derived Cells
Funder
National Health and Medical Research Council
Funding Amount
$758,678.00
Summary
Cancers of the stomach and the colon are a major health burden. Despite our increased molecular understanding of the mutation that cause these cancers our treatment options are very limited. Here we will use sophisticated and validated mouse models for these cancers to establish how blood-borne cells contribute to the growth and spreading of these cancer. We will use these models to establish highly effective treatment combinations of therapeutic agents that are already undergoing preclinical te ....Cancers of the stomach and the colon are a major health burden. Despite our increased molecular understanding of the mutation that cause these cancers our treatment options are very limited. Here we will use sophisticated and validated mouse models for these cancers to establish how blood-borne cells contribute to the growth and spreading of these cancer. We will use these models to establish highly effective treatment combinations of therapeutic agents that are already undergoing preclinical testing.Read moreRead less
Osteosarcoma is the most common tumour of bone. Recent success in targeting immune checkpoint blockers such as Programmed death-1 (PD-1) in genomically complex tumours suggests that osteosarcomas may be amenable to such strategies. We will characterise the role of the PD-1 pathway in osteosarcoma development and growth. Using preclinical mouse models we will investigate the biology of the PD-1 pathway and study its potential as a therapeutic target in advanced and resectable osteosarcoma.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100091
Funder
Australian Research Council
Funding Amount
$250,000.00
Summary
A five laser multichannel flow cytometry cell sorter for the University of New South Wales as part of an advanced flow cytometry network. Flow cytometry is a technique for counting and examining microscopic particles, such as cells and chromosomes, by suspending them in a stream of fluid and passing them by an electronic detection apparatus. This project will establish such advanced cell sorting instrumentation at the University of New South Wales, providing this capability to a wide range of re ....A five laser multichannel flow cytometry cell sorter for the University of New South Wales as part of an advanced flow cytometry network. Flow cytometry is a technique for counting and examining microscopic particles, such as cells and chromosomes, by suspending them in a stream of fluid and passing them by an electronic detection apparatus. This project will establish such advanced cell sorting instrumentation at the University of New South Wales, providing this capability to a wide range of researchers in diverse fields. The project will also provide a basis for establishing a flow cytometry network with partner institutes University of Sydney and the University of Technology, Sydney.Read moreRead less
How do mechanical cues regulate tissue renewal and tumour progression? Imbalances between cell production and cell death in tissues can be catastrophic, leading to major global health issues such as cancer. This project will use modified mice and protein-protein interaction based techniques to identify how changes in the mechanical properties of tissues regulate the balance between cell production and cell death.
EGFR-directed radioimmunotherapy combined with chemotherapy and DNA repair inhibition: development towards clinical application for aggressive cancers. Pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC) are aggressive diseases which lack effective therapies in clinical use. A novel and curative therapy was developed against PDAC and TNBC which involves targeted radiotherapy combined with chemotherapy and DNA damage response inhibition. This project will develop a “p ....EGFR-directed radioimmunotherapy combined with chemotherapy and DNA repair inhibition: development towards clinical application for aggressive cancers. Pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC) are aggressive diseases which lack effective therapies in clinical use. A novel and curative therapy was developed against PDAC and TNBC which involves targeted radiotherapy combined with chemotherapy and DNA damage response inhibition. This project will develop a “preclinical data package” comprising a biological rationale and preclinical evidence of safety and efficacy that together would justify an early phase clinical trial. This package includes the choice of formulations, mechanism of action and safety studies. This development will have an immediate impact for PDAC and TNBC patients and a future impact on other EGFR-positive cancers.Read moreRead less